IC
Ikarian Capital Portfolio holdings
AUM
$302M
This Quarter Return
+7.96%
1 Year Return
+65.21%
3 Year Return
+441.33%
5 Year Return
+548.26%
10 Year Return
–
AUM
$322M
AUM Growth
+$322M
(+0.48%)
Cap. Flow
-$129M
Cap. Flow
% of AUM
-40.09%
Top 10 Holdings %
Top 10 Hldgs %
44.05%
Holding
134
New
20
Increased
8
Reduced
29
Closed
9
Top Buys
| 1 |
Viridian Therapeutics
VRDN
|
$11.4M |
| 2 |
Ultragenyx Pharmaceutical
RARE
|
$9.94M |
| 3 |
Arcus Biosciences
RCUS
|
$9.16M |
| 4 |
Spyre Therapeutics
SYRE
|
$8.89M |
| 5 |
Avalo Therapeutics
AVTX
|
$8.7M |
Top Sells
| 1 |
Sarepta Therapeutics
SRPT
|
$18.7M |
| 2 |
Soleno Therapeutics
SLNO
|
$11.3M |
| 3 |
Nuvalent
NUVL
|
$10.2M |
| 4 |
Crinetics Pharmaceuticals
CRNX
|
$8.27M |
| 5 |
Amgen
AMGN
|
$8.06M |
Sector Composition
| 1 | Healthcare | 99.61% |
| 2 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
Galectin Therapeutics
GALT
$288M
| – | – |
0
| – | – |
|
127
Madrigal Pharmaceuticals
MDGL
$9.7B
| – | – |
0
| – | – |
|
128
NewAmsterdam Pharma
NAMS
$2.8B
| – | – |
0
| – | – |
|
129
Neurocrine Biosciences
NBIX
$13.5B
| – | – |
-40,000
| Closed | -$5.51M |
|
130
Neumora Therapeutics
NMRA
$283M
| – | – |
0
| – | – |
|
131
Praxis Precision Medicines
PRAX
$980M
| – | – |
0
| – | – |
|
132
Prothena Corp
PRTA
$452M
| – | – |
0
| – | – |
|
133
Sana Biotechnology
SANA
$759M
| – | – |
0
| – | – |
|
134
Solid Biosciences
SLDB
$448M
| – | – |
0
| – | – |
|